https://www.selleckchem.com/pr....oducts/SB-743921.htm
Immune checkpoint inhibitors (ICI) represent a cornerstone in cancer treatment. However, the peculiarity of immune response, determining distinctive response patterns and toxicity events, challenges the conventional response criteria. Therefore, the effective tumor response and the real clinical benefit cannot be demonstrated adequately. In this context, recent studies using 2-deoxy-2-[18F]fluoro-D-glucose ([18F]) positron emission tomography/computed tomography (PET/CT) have shown promising results for therapeutic monitoring during I
Like
Comment
Share
